A company we are supporting is currently finalizing a substantial Series A round with leading European investors. To complement the team, they are currently looking for an experienced drug developer. The successful candidate will be part of the management team and contribute to strategic and operational decision making as well as taking full responsibility for the development and characterization of early candidates up to IND/start of Phase I.
The company
The company is devoted to developing therapeutics for advanced liver diseases, with the vision to redefine the state of care for patients suffering from fibrosis, cirrhosis and HCC. They have a lead humanized monoclonal antibody against a novel target with a new MoA, which is fundamental in advanced liver disease processes. The antibody is now being brought into pre-clinical pharmacology and tox studies and prepared for GMP manufacturing. The company has also access to a genomics based platform technology for patient selection, surrogate efficacy readouts and discovery of additional liver disease therapeutics.
We are looking for
If you are looking to help building, together with the senior leadership team, a transformative biotech from scratch, bring deep development experience (lead characterization; animal efficacy and toxicity; PK/PD; biomarker and assay development; with CMC expertise being advantageous but not mandatory), have a track record developing and conducting (together with DRA) health authority briefings and filings for Phase I studies as well as selecting and managing external contract organizations and other partners, then we would love to hear from you.
To get in touch please send an email to stephan.emmerth@baselaunch.ch .